Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TR 701

Known as: TR-701, TR701 cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Introduction: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug… Expand
Highly Cited
2012
Highly Cited
2012
ABSTRACT Tedizolid (TR-700, formerly torezolid) is the active moiety of the prodrug tedizolid phosphate (TR-701), a next… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
2012
2012
ABSTRACT The in vitro activity of tedizolid (previously known as torezolid, TR-700) against penicillin-resistant Streptococcus… Expand
Highly Cited
2011
Highly Cited
2011
ABSTRACT Torezolid phosphate (TR-701) is the phosphate monoester prodrug of the oxazolidinone TR-700 which demonstrates potent in… Expand
Review
2011
Review
2011
The success of linezolid stimulated significant efforts to discover new agents in the oxazolidinone class. Over a dozen… Expand
Highly Cited
2010
Highly Cited
2010
ABSTRACT This study assessed the spectrum of activity of torezolid (TR-700), the active moiety of torezolid phosphate (TR-701… Expand
Highly Cited
2009
Highly Cited
2009
ABSTRACT TR-700 (torezolid), the active moiety of the novel oxazolidinone phosphate prodrug TR-701, is highly potent against gram… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2009
Highly Cited
2009
ABSTRACT TR-701 is the prodrug of the microbiologically active molecule TR-700, a novel orally and intravenously administered… Expand
2009
2009
BACKGROUND TR-700, the active component of the oxazolidinone prodrug TR-701, has demonstrated potent activity against numerous… Expand
Highly Cited
2008
Highly Cited
2008
ABSTRACT TR-701 is the orally active prodrug of TR-700, a novel oxazolidinone that demonstrates four- to eightfold-greater… Expand
  • table 1
  • table 2
  • table 3
  • figure 1